What is it?
Kisspeptin is a family of natural signaling peptides that helps the brain start the reproductive hormone cascade.
Gathering the record
Loading the next view…
Relay is organizing the evidence and source boundaries.
Gathering the record
Relay is organizing the evidence and source boundaries.
KISS1-derived reproductive neuropeptide / KISS1R agonist
Kisspeptin is one of the brain's upstream “start signals” for the reproductive hormone system. Human studies show that specific research forms can raise LH and FSH, trigger egg maturation during monitored IVF, and change sexual-processing signals in small controlled trials. It is not an approved fertility, testosterone, or sexual-function drug, and repeated exposure can make the hormone response fade.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Kisspeptin is a family of natural signaling peptides that helps the brain start the reproductive hormone cascade.
Researchers are studying whether specific kisspeptin forms can trigger egg maturation during monitored fertility treatment, temporarily stimulate reproductive hormones, or change sexual-processing signals without directly replacing downstream hormones.
Early human studies show that kisspeptin-54 can trigger egg maturation in monitored in-vitro fertilization programs and that kisspeptin can temporarily raise reproductive hormones. Small controlled studies also found acute brain-imaging and questionnaire signals related to sexual desire.
Comparative fertility effectiveness, durable symptom benefit, long-term safety, the best molecular form, and product identity remain unresolved. Repeated exposure can reduce the hormone response, and no kisspeptin product is FDA approved.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
An early clinical study investigated a specific kisspeptin-54 preparation as an egg-maturation trigger within a fully monitored in-vitro fertilization program.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Phase 2 IVF studies and multiple controlled physiology trials cover SubQ, IV, and intranasal kisspeptin, but most studies are small and no product is approved.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Acute LH and FSH responses are reproducible, while fertility, testosterone, sexual-function, and long-term safety conclusions remain preliminary and schedule dependent.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The dose-ranging study had no active trigger comparator and does not establish superiority. A monitored fertility-center protocol cannot be transferred to other kisspeptin forms, populations, products, or self-directed use. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Phase 2 IVF oocyte-maturation studies and multiple small randomized controlled human physiology trials
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Comparative clinical effectiveness, long-term safety, durable fertility or symptom outcomes, optimal form and schedule, and product-specific identity and stability
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
KISS1-derived peptides activate KISS1R on GnRH neurons. GnRH then signals the pituitary to release LH and FSH, which regulate gonadal hormone production, follicular development, ovulation, and sperm production.
Human studies have used specific forms, especially kisspeptin-54 and kisspeptin-10. They differ in length, pharmacokinetics, formulation, route, and research setting even though they share KISS1R activity.
Two fertility-center studies showed mature oocytes, fertilization, pregnancies, and live births after a single kisspeptin-54 trigger within a complete ovarian-stimulation and embryo-transfer protocol.
Oocyte maturation occurred in 95% and no participant developed moderate, severe, or critical OHSS, but every participant received kisspeptin and there was no hCG or GnRH-agonist control arm.
Small controlled physiology experiments with kisspeptin-10 produced rapid LH responses, more LH pulses during infusion, and short-term testosterone increases.
In women with hypothalamic amenorrhea, twice-daily kisspeptin-54 responses became much smaller over two weeks. In three men studied in 2026, LH declined from its peak during a 24-hour continuous kisspeptin-10 infusion.
Small studies found acute LH/FSH release and temporarily increased LH pulses, while repeated exposure could desensitize the response.
Acute intravenous kisspeptin-54 changed sexual-processing brain activity in women and men with HSDD. The men's study also reported secondary arousal and tumescence signals.
The human literature describes investigational research formulations and monitored study protocols rather than an approved consumer product or prescribing label.
Human research has used intravenous, subcutaneous, and intranasal administration under different formulations, monitoring plans, populations, and endpoints.
The 2025 intranasal study reported stability for its own pharmaceutical formulation, but there is no FDA-approved consumer label covering generic kisspeptin powder or mixed products.
Mechanisms
KISS1-derived peptides share a C-terminal RF-amide sequence and activate KISS1R/GPR54, a G-protein-coupled receptor expressed on gonadotropin-releasing-hormone neurons. This stimulates GnRH release and downstream pituitary LH and FSH secretion. Human loss-of-function genetics establish the pathway's importance for puberty and reproduction. Clinical research has used kisspeptin-54 and kisspeptin-10 with different pharmacokinetics and intravenous, subcutaneous, or study-specific intranasal formulations. Phase 2 IVF studies support experimental oocyte maturation; smaller studies document hormone pulsatility, acute sexual-processing effects, and schedule-dependent tachyphylaxis. No approved product or universal protocol exists.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized double-blind crossover placebo-controlled study
12 healthy men, 12 healthy women, and 10 women with hypothalamic amenorrhea
Intranasal kisspeptin-54 increased LH in all three groups, with the largest response in the hypothalamic-amenorrhea group. No side effects or adverse events were encountered during the short study.
Study administration: A study-specific intranasal kisspeptin-54 formulation at several protocol-defined levels or placebo
Limitations: This was an early hormone-response study, not a fertility or symptom-outcome trial. The formulation's reported 60-day refrigerated stability cannot be transferred to other products or routes.
Double-blind two-way crossover placebo-controlled trial
37 men with HSDD; 32 completed both visits
Kisspeptin changed sexual-processing brain activity. Secondary analyses included up to 56% greater penile tumescence during a sexual video and improvement in selected desire or arousal measures.
Study administration: Intravenous kisspeptin-54 or matched placebo
Limitations: This was a single-center acute infusion experiment. Secondary physiological and questionnaire findings do not establish a durable treatment effect.
Double-masked two-way crossover placebo-controlled trial
40 premenopausal women with HSDD; 32 completed both visits
Kisspeptin changed activity in brain regions involved in sexual and facial-attraction processing and was well tolerated during the acute visits.
Study administration: Intravenous kisspeptin-54 or matched placebo
Limitations: The primary outcomes were acute neuroimaging signals. The trial did not establish durable symptom improvement, real-world sexual-function benefit, or an approved treatment.
Open-label randomized adaptive dose-allocation study
60 women undergoing IVF who were at high risk of OHSS
Oocyte maturation occurred in 95% of women. Among 51 embryo transfers, biochemical pregnancy was 63%, clinical pregnancy 53%, and live birth 45%; no participant developed moderate, severe, or critical OHSS.
Study administration: A protocol-defined single subcutaneous kisspeptin-54 trigger within a monitored IVF cycle
Limitations: There was no active trigger comparator, the study was open-label and dose-adaptive, and the sample was selected for high OHSS risk. It does not prove superiority or establish an approved IVF trigger.
Prospective adaptive dose-ranging trial
53 women with subfertility undergoing IVF
Egg maturation occurred at every studied level. Fertilization and embryo transfer occurred in 49 of 53 women; biochemical pregnancy occurred in 40% and clinical pregnancy in 23%.
Study administration: A protocol-defined single subcutaneous kisspeptin-54 trigger after ovarian stimulation
Limitations: This was a dose-ranging fertility-center study without an hCG or GnRH-agonist comparator. The protocol was a complete monitored IVF program, not a general dosing template.
Single-blinded within-person vehicle and dose-ranging infusions
5 women with hypothalamic amenorrhea
Kisspeptin temporarily increased LH pulsatility in all five participants, but each participant's largest response occurred at a different studied level.
Study administration: Intravenous vehicle or kisspeptin-54
Limitations: This five-person physiology study measured temporary hormone patterns, not restoration of menstruation, ovulation, fertility, or long-term clinical benefit.
Intravenous bolus dose response plus short continuous infusions
Small groups of healthy men
Kisspeptin-10 rapidly increased LH. In four-person infusion experiments, LH pulse frequency and secretory mass increased and testosterone rose during the observation period.
Study administration: Research-grade intravenous kisspeptin-10 or vehicle
Limitations: The component experiments enrolled only four to six men. Hormone changes do not establish long-term testosterone treatment, symptom improvement, fertility, or safety.
Randomized double-blind parallel placebo-controlled study
10 women with hypothalamic amenorrhea
The first kisspeptin exposure sharply increased LH and FSH, but those responses were markedly reduced by the fourteenth treatment day. No meaningful change in LH pulsatility or ultrasound reproductive activity was observed.
Study administration: Twice-daily subcutaneous kisspeptin-54 or saline under a research protocol
Limitations: Only five women received kisspeptin. The main result is a schedule-dependent desensitization signal, not evidence for restored cycles, ovulation, pregnancy, or a self-directed protocol.
Uncontrolled continuous-infusion physiology study
3 healthy adult men
LH rose five- to eightfold above baseline, then declined by 13% to 47% from its peak before the infusion ended; FSH and testosterone rose more modestly.
Study administration: Continuous intravenous kisspeptin-10 infusion
Limitations: Three participants, no placebo arm, and no clinical outcome. The study describes a dynamic hormone response and cannot establish a therapeutic infusion regimen.
Acute bolus comparison plus uncontrolled short infusion
5 men with type 2 diabetes and mild biochemical hypogonadism plus 7 healthy comparison participants
LH increased after the acute exposure in both groups. During the four-person infusion experiment, LH secretion and serum testosterone increased in the men with type 2 diabetes.
Study administration: Intravenous kisspeptin-10
Limitations: Only five affected participants were studied and just four completed the infusion. No glucose, HbA1c, diabetes-complication, symptom, fertility, or long-term outcome was tested.
Safety snapshot
The 60-person high-OHSS-risk IVF study reported encouraging outcomes, but it did not prove kisspeptin was safer or better than standard triggers.
Controlled human evidenceA zero-event result in 60 selected participants does not define rare risk or comparative effectiveness.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryInvestigational; no FDA-approved kisspeptin drug product located Comparative clinical effectiveness, long-term safety, durable fertility or symptom outcomes, optimal form and schedule, and product-specific identity and stability
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-06-02 · PMID 42230485 · NCT01438073 · DOI 10.1007/s42000-026-00795-y
2025-05-01 · PMID 40215751 · DOI 10.1016/j.ebiom.2025.105689
2023-02-01 · PMID 36735255 · ISRCTN17271094 · DOI 10.1001/jamanetworkopen.2022.54313
2022-10-03 · PMID 36287566 · ISRCTN17271094 · DOI 10.1001/jamanetworkopen.2022.36131
2015-09-01 · PMID 26192876 · NCT01667406 · DOI 10.1210/jc.2015-2332
2014-08-01 · PMID 25036713 · NCT01667406 · DOI 10.1172/JCI75730
2014-06-01 · PMID 24517142 · DOI 10.1210/jc.2013-1569
2013-07-01 · PMID 23153270 · DOI 10.1111/cen.12103
2011-08-01 · PMID 21632807 · DOI 10.1210/jc.2011-0089
2009-11-01 · PMID 19820030 · DOI 10.1210/jc.2009-0406
2003-10-23 · PMID 14573733 · DOI 10.1056/NEJMoa035322